UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 5)

The Female Health Company

---------------------------------------------
(Name of Issuer)

Common Stock, $0.01 par value

---------------------------------------------
(Title of Class of Securities)

314462 10 2

---------------------------------------------
(CUSIP Number)

Stephen M. Dearholt
741 N. Milwaukee Street, Suite 500, Milwaukee, Wisconsin 53202

---------------------------------------------
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)

June 14, 2000

---------------------------------------------
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Rules 13d-1(e), 13d-1(f) or 13d-1(g), check the following
box [ ].

Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 13d-7(b) for other
parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
SCHEDULE 13D

CUSIP No. 314462 10 2

NAMES OF REPORTING PERSONS

1    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only).

    Stephen M. Dearholt

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

2                                                              (a) [ ]
                                                               (b) [ ]

SEC USE ONLY

3

SOURCE OF FUNDS (See Instructions)

4

PF

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [ ]

5

CITIZENSHIP OR PLACE OF ORGANIZATION

6

Wisconsin, USA

SOLE VOTING POWER

7

NUMBER OF

1,855,722

SHARES

SHARED VOTING POWER

8

640,998

OWNED BY

EACH

SOLE DISPOSITIVE POWER

9

1,855,722

REPORTING PERSON

SHARED DISPOSITIVE POWER

10

640,998

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

11

2,496,720

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ]

(See Instructions)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

13

17.63%

TYPE OF REPORTING PERSON (See Instructions)

IN
This amendment is being filed to report the acquisition of additional shares of common stock ("Issuer Common Stock") of The Female Health Company (the "Company") by Mr. Dearholt as described in Item 5.

Item 5. Interest in Securities of the Issuer

<table>
<thead>
<tr>
<th>Name of Beneficial Owner</th>
<th>Amount of Beneficial Ownership</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Shares of Issuer Common Stock</td>
</tr>
<tr>
<td>Stephen M. Dearholt (1)(2)</td>
<td>2,496,720</td>
</tr>
</tbody>
</table>

(1) Includes options to purchase 50,000 shares (which are currently exercisable) granted pursuant to the terms of the Company's Outside Director Stock Option Plan.

(2) Includes 524,742 shares owned directly by Mr. Dearholt and warrants to purchase 1,172,500 shares which are currently exercisable. Also includes the following shares which Mr. Dearholt may be deemed to beneficially own: 69,500 shares held by the Dearholt, Inc. Profit Sharing Plan; 9,680 shares held by the Response Marketing Money Purchase Plan; 11,200 shares held in a self-directed IRA; 162,898 shares held by the Mary C. Dearholt Trust of which Mr. Dearholt, a sibling and his mother are trustees; 18,100 shares held by Mr. Dearholt's minor child; 418,100 shares held by the James W. Dearholt Trust of which Mr. Dearholt is a co-trustee with a sibling, and 60,000 shares of preferred stock held by the Mary C. Dearholt Trust that are convertible share-for-share into Issuer Common Stock. Mr. Dearholt shares the power to vote and dispose of 640,998 shares of Issuer Common Stock (including 60,000 shares of Preferred Stock convertible into Issuer Common Stock) held by the Mary C. Dearholt Trust and the James W. Dearholt Trust. Mr. Dearholt has sole power to vote and dispose of the remaining shares of Issuer Common Stock reported herein, except that North Central Trust has the sole power to vote and dispose of the 9,680 shares of Issuer Common Stock held by the Response Marketing Money Purchase Plan.

On June 14, 2000, the James W. Dearholt Trust, for which Mr. Dearholt serves as a co-trustee, purchased 400,000 shares of Issuer Common Stock from the Company at $.50 per share, which per share price represented a discount from market price. All shares were purchased solely for investment purposes.
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

/s/ Stephen M. Dearholt

Stephen M. Dearholt

Dated: June 26, 2000